Biography
Executive with 25+ years in pharma, industry and international business. Former CEO of Infamed Group, with expertise in operations, M&A, international law and intellectual property. Independent executive and advisor since 2025.
Experience
Led international pharmaceutical operations, manufacturing, regulatory affairs, IP, product registration and contract manufacturing across CIS and European markets.
Current context
Confidential pharmaceutical localisation mandates in Jordan: registration strategy and eCTD, GMP/CMO, APIs, analytics and packaging. In the UAE, coordination with Mashreq Bank on financial and organisational matters.
Career
My experience spans pharmaceutical operations, manufacturing, procurement, international development, capital investment, M&A and industry leadership.
2025 — present
Vienna · independent practice
Confidential pharmaceutical localisation mandates in Jordan: registration strategy and eCTD, GMP/CMO, APIs, analytics and packaging. In the UAE, coordination with Mashreq Bank on financial and organisational matters.
12/2021 — present
Appliner · Moscow / Dubai
Strategy and corporate development of a no-code/low-code and AI platform for enterprise applications built by business users.
2010 — 2025
INFAMED GROUP · MEGAINPHARM GmbH
Group revenue exceeded €120M in 2024; profit grew 17% versus 2023. Manufacturing with 300+ staff and an industrial park with 500+ professionals. A €35M+ investment programme covering API production, sterile units and a GDP warehouse. 9+ GMP/GDP inspections; a portfolio of 17+ products with registrations across 27 countries. International patents and trademarks; M&A and corporate transactions of €10–170M. Supported the sale of the group in 2025.
2021 — 2022
ISPE Eurasian Affiliate · ISPE EAEU
Served on the Board of the Eurasian Affiliate of the International Society for Pharmaceutical Engineering. Advanced digitalization initiatives, including an open platform for pharmaceutical-market participants and a proposal for industry-wide digital policy; contributed to working sessions and affiliate planning.
2007 — 2008
Uniplast Trading · Retal
PX–PTA–PET licensor selection: Axens selected for a PX unit planned at the Nadvirna refinery. Alpine-water bottling project with the Habsburg family in Koralpe, on the Styria/Carinthia border: Biola brand, 19 km pipeline, JV and business plan. The water project was frozen in the 2008 crisis.
2006
Khimmashbank
Prepared the sale of an 84.72% stake and personally signed the deal with Oleg Tinkov. The bank became Tinkoff Credit Systems, today T-Bank.
View the transaction2005 — 2008
RETAL INDUSTRIES Ltd
Led procurement across 27 manufacturing sites in Europe and Eurasia within a multinational industrial group generating approximately USD 3.5B in annual turnover.
2001 — 2010
MEGA-PLASTIK GmbH
International procurement and distribution in Central and Eastern Europe, global supplier relationships and refinery reconstruction. Part of the Mashcenter group; the company was subsequently liquidated.
1999 — 2010
Mashcenter LLC
Raw-material and equipment procurement: a purchasing budget of approximately USD 10M a year and 2 direct reports, supporting a business with around USD 250M turnover. Led M&A execution and coordinated advisers and regulatory processes. Concurrent role within the Mashcenter / Mega-Plastik group.
Companies & products
Selected companies from my professional career and flagship pharmaceutical brands from the Infamed K portfolio.
Companies
Infamed Group · CEO (2023–2024); Megainpharm GmbH · Managing Director (2010–2025)
INDUSTRIESRETAL INDUSTRIES Ltd · Director of Purchasing, 2005–2008
Flagship products
Original antiseptic medicine
Ophthalmic antiseptic medicine
The product brands are shown in the context of my work at Infamed Group.
Biography
Executive MBA · 2021–2023; Digital Transformation, CDTO · 2020–2021
PhD in Civil Law (Candidate of Legal Sciences) · 2006
Law & Economics · 2003
Specialist diploma in Civil Law · 1998–2003
Collaboration
Taking a pharmaceutical project into a new market
International contract and IP architecture
Negotiations across business, manufacturing and regulators
Crisis coordination for complex international projects
Contact
I welcome conversations about international pharma business, complex cross-border projects and long-term collaboration.
From October 2026 · permanent or interim roles · Vienna, travel-ready